Mettler-Toledo International (NYSE:MTD) Earns Equal Weight Rating from Analysts at Morgan Stanley

Morgan Stanley began coverage on shares of Mettler-Toledo International (NYSE:MTD) in a note issued to investors on Tuesday, MarketBeat reports. The firm set an “equal weight” rating and a $1,550.00 price target on the medical instruments supplier’s stock. Morgan Stanley’s price objective would indicate a potential upside of 5.61% from the company’s current price.

MTD has been the topic of several other reports. Evercore ISI boosted their target price on Mettler-Toledo International from $1,275.00 to $1,400.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Stifel Nicolaus boosted their price objective on Mettler-Toledo International from $1,450.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Barclays increased their target price on Mettler-Toledo International from $1,350.00 to $1,600.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. JPMorgan Chase & Co. lifted their price target on Mettler-Toledo International from $1,200.00 to $1,285.00 and gave the company a “neutral” rating in a report on Thursday, October 9th. Finally, Robert W. Baird upped their price target on shares of Mettler-Toledo International from $1,210.00 to $1,230.00 and gave the stock a “neutral” rating in a research report on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $1,419.55.

Mettler-Toledo International Trading Down 0.6%

Shares of NYSE MTD opened at $1,467.73 on Tuesday. The business has a fifty day simple moving average of $1,372.96 and a 200 day simple moving average of $1,277.21. The firm has a market capitalization of $29.98 billion, a price-to-earnings ratio of 37.17, a PEG ratio of 4.19 and a beta of 1.40. Mettler-Toledo International has a one year low of $946.69 and a one year high of $1,525.17.

Mettler-Toledo International (NYSE:MTD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $11.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.62 by $0.53. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $997.36 million. Mettler-Toledo International had a net margin of 21.46% and a negative return on equity of 476.07%. The company’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $10.21 earnings per share. Mettler-Toledo International has set its Q4 2025 guidance at 12.680-12.880 EPS. FY 2025 guidance at 42.050-42.250 EPS. On average, research analysts anticipate that Mettler-Toledo International will post 42.71 earnings per share for the current fiscal year.

Insider Transactions at Mettler-Toledo International

In related news, insider La Guerroniere Marc De sold 6,055 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $1,488.18, for a total transaction of $9,010,929.90. Following the completion of the sale, the insider directly owned 187 shares of the company’s stock, valued at approximately $278,289.66. This represents a 97.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Shawn Vadala sold 1,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $1,511.00, for a total transaction of $1,511,000.00. Following the sale, the chief financial officer directly owned 5,288 shares of the company’s stock, valued at $7,990,168. This represents a 15.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 19,565 shares of company stock valued at $28,683,737. Corporate insiders own 1.94% of the company’s stock.

Institutional Trading of Mettler-Toledo International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of Mettler-Toledo International by 42.1% in the third quarter. Versant Capital Management Inc now owns 27 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 8 shares during the last quarter. SJS Investment Consulting Inc. raised its stake in Mettler-Toledo International by 2,700.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 28 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Salomon & Ludwin LLC bought a new stake in Mettler-Toledo International in the 3rd quarter valued at $43,000. Root Financial Partners LLC acquired a new stake in Mettler-Toledo International during the 3rd quarter valued at $42,000. Finally, WPG Advisers LLC bought a new position in Mettler-Toledo International during the first quarter worth $41,000. 95.07% of the stock is owned by institutional investors.

Mettler-Toledo International Company Profile

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments.